Prestige Consumer Healthcare (NYSE:PBH) Updates FY 2026 Earnings Guidance

Key Points

• Prestige Consumer Healthcare updated its FY 2026 earnings guidance, projecting earnings per share between $4.500 and $4.580, below the consensus of $4.770.
• The company reported quarterly earnings of $1.32 per share, surpassing estimates, with revenue of $296.52 million, reflecting a 7.0% increase from the previous year.
• Analyst ratings for Prestige Consumer Healthcare have improved, with multiple brokerages trending towards a "buy" rating and a consensus price target of $93.33.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 4.500-4.580 for the period, compared to the consensus EPS estimate of 4.770. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Analyst Ratings Changes

A number of research firms have commented on PBH. Canaccord Genuity Group decreased their target price on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating on the stock in a research report on Friday. Royal Bank Of Canada raised Prestige Consumer Healthcare to a "hold" rating in a research note on Thursday, May 8th. Finally, Wall Street Zen lowered shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research report on Saturday. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, Prestige Consumer Healthcare presently has a consensus rating of "Hold" and an average target price of $93.33.

Prestige Consumer Healthcare Stock Performance

NYSE:PBH traded down $1.27 during trading on Monday, reaching $64.31. The company's stock had a trading volume of 347,898 shares, compared to its average volume of 374,141. The firm has a 50 day moving average of $79.26 and a 200-day moving average of $82.09. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.99 and a current ratio of 4.38. The firm has a market cap of $3.16 billion, a price-to-earnings ratio of 15.10, a price-to-earnings-growth ratio of 1.98 and a beta of 0.43. Prestige Consumer Healthcare has a 12 month low of $63.49 and a 12 month high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.95 EPS for the quarter, missing analysts' consensus estimates of $1.01 by ($0.06). The business had revenue of $249.53 million for the quarter, compared to the consensus estimate of $260.71 million. Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. Prestige Consumer Healthcare's revenue was down 6.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.90 EPS. Research analysts expect that Prestige Consumer Healthcare will post 4.5 EPS for the current fiscal year.

Institutional Trading of Prestige Consumer Healthcare

Institutional investors and hedge funds have recently made changes to their positions in the business. Geneos Wealth Management Inc. boosted its position in Prestige Consumer Healthcare by 92.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company's stock worth $48,000 after purchasing an additional 269 shares in the last quarter. Cetera Investment Advisers increased its stake in shares of Prestige Consumer Healthcare by 70.6% in the 2nd quarter. Cetera Investment Advisers now owns 8,689 shares of the company's stock worth $694,000 after acquiring an additional 3,596 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Prestige Consumer Healthcare by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,490 shares of the company's stock worth $2,535,000 after acquiring an additional 1,289 shares during the last quarter. AQR Capital Management LLC increased its position in shares of Prestige Consumer Healthcare by 11.9% during the 1st quarter. AQR Capital Management LLC now owns 30,056 shares of the company's stock worth $2,558,000 after purchasing an additional 3,200 shares during the last quarter. Finally, Jane Street Group LLC increased its position in shares of Prestige Consumer Healthcare by 204.0% during the 1st quarter. Jane Street Group LLC now owns 104,802 shares of the company's stock worth $9,010,000 after purchasing an additional 70,330 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.